Vesicor Therapeutics Appoints Michael Tolentino as CEO Ahead of Planned Merger and Clinical Milestones

The appointment of Michael Tolentino, M.D., as chief executive officer of Vesicor Therapeutics Inc. represents a strategic leadership transition as the company prepares for critical regulatory and corporate development phases. Effective March 17, 2026, Tolentino succeeds founder Luo Feng, Ph.D., who will transition to the role of chief scientific officer. This change occurs while Vesicor advances its p53-based cancer therapeutic platform and prepares for Investigational New Drug (IND)-enabling studies and a planned submission to the U.S. Food and Drug Administration (FDA). The company is also the proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (Nasdaq: BKHA, BKHAU, BKHAR), and Tolentino's appointment is expected to support the execution of Vesicor's growth strategy and progression toward this proposed merger.

Dr. Tolentino brings more than two decades of biotechnology leadership experience to Vesicor, with a career spanning drug discovery, clinical development, and company building. His background includes involvement in the development of the cancer drug Avastin and leadership positions at multiple biotechnology firms. This expertise positions him to guide Vesicor through the complex process of advancing a novel cancer therapy. The company's focus on p53-based therapeutics targets a critical tumor suppressor pathway that is dysfunctional in many cancers, representing a significant area of oncology research. The leadership transition aligns with the company's move from foundational research toward clinical and regulatory milestones, which are essential for attracting further investment and achieving long-term viability in the competitive biopharmaceutical landscape.

The corporate context of this announcement is equally significant. Black Hawk Acquisition Corporation is a special purpose acquisition company (SPAC) formed to effect a merger, share exchange, asset acquisition, or similar business combination. The proposed merger with Vesicor would provide the latter with public market access and capital to fund its development programs. For more information on Black Hawk Acquisition Corporation, please visit https://www.bhspac.com/. The press release containing this announcement was distributed through MissionIR, a specialized communications platform within the Dynamic Brand Portfolio at IBN that focuses on enhancing the visibility of companies within the investment community. For more information on MissionIR, please visit https://www.MissionIR.com.

The implications of this leadership appointment are multifaceted. For Vesicor, installing a CEO with extensive clinical and corporate development experience signals a maturation of the company as it approaches the translational stage of moving a therapy from the laboratory toward human trials. It demonstrates a commitment to navigating the regulatory pathway required for FDA approval, a process that demands specific expertise in clinical trial design, manufacturing, and compliance. For investors and stakeholders in Black Hawk Acquisition Corporation, the appointment of a seasoned executive like Tolentino may bolster confidence in Vesicor's management team and its ability to execute on its business plan post-merger. It addresses a common concern in SPAC transactions regarding the operational readiness of the target company's leadership to function as a public entity. Furthermore, in the broader biotechnology sector, such appointments highlight the critical importance of leadership transitions as companies evolve from research-focused entities to clinical-stage organizations tasked with delivering therapies to patients.